Antiviral Drugs Market Share Analysis Report, 2022-2030
The global Antiviral Drugs market size was estimated at USD 48 billion in 2021 and is expected to surpass around USD 65.1 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 4.1% during the forecast period 2022 to 2030.
Growth Factors:
The introduction of the generic version of antiviral medicines and growing awareness about the availability of various vaccines for viral infections is affecting the growth during the forecast period.
However, the increasing prevalence of viral infections such as HIV, Herpes, Influenza, and others are expected to increase the demand for antiviral medicines over the forecast period. For instance, according to UNAIDS, in 2020, more than 37 million individuals were living with HIV across the globe. Out of these, approximately 1.5 million new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has significantly increased market growth in 2020 whereas, a negative impact of the pandemic has been observed for other applications of antiviral drugs.
The increasing incidence of viral infection across the globe is a major factor driving the demand for antiviral drugs over the forecast period. According to WHO, globally, an estimated 325 million people are living with hepatitis infection and out of these, around 71 million have chronic hepatitis C virus infection. Moreover, the U.S. Department of Health and Human Services has estimated that 2.4 million people are living with hepatitis C in the United States and around 850,000 individuals in the country have hepatitis B infection. An increasing base of patients is anticipated to increase the demand for antiviral drugs globally.
Increasing approval and expected commercialization of novel medicines for viral infections are anticipated to drive market growth. For instance, in November 2020, the U.S. FDA has approved a supplemental New Drug Application for Roche’s Xofluza for the treatment of influenza in patients 12 years of age and older. Moreover, the major players in the market have launched many novel medicines in 2 to 3 years for the treatment of viral infections. For instance, Gilead Sciences, Inc. has launched Biktarvy, Symtuza, and Veklury for the treatment of viral infections. Furthermore, GlaxoSmithKline plc. has launched Dovato, Cabenuva, and Juluca for the treatment of diseases caused by the virus. An increase in the introduction of novel products in the market will drive growth over the next 2 to 3 years.
The outbreak of the COVID-19 pandemic has significantly increased the demand for antiviral medicines globally. The treatment of novel coronavirus has increased the demand for broad-spectrum antiviral drugs to manage the disease. Remdesivir, favipiravir, oseltamivir, and other combination medicines are highly prescribed for the treatment of COVID-19. Moreover, governments are increasing funding to pharmaceutical companies to develop novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government has announced an investment of more than USD 3 billion to fasten the discovery, development, and manufacturing of antiviral medicines for COVID-19 treatment. The rising incidence of disease coupled with increasing R&D will increase the demand for antiviral drugs in the next 2 to 3 years.
Increasing collaborations for the development and manufacturing of antiviral drugs are expected to result in the development of a high number of novel drugs in the coming years. The key players in the market are collaborating for the R&D of new therapies to reduce the burden of viral infection treatment. For instance, in 2020, Gilead Sciences, Inc. has signed licensing agreement with pharmaceutical manufacturers such as Cipla Ltd., Hetero Labs Ltd., Dr. Reddy's Laboratories Ltd., Mylan, and others to expand the supply of remdesivir.
Report Scope of the Antiviral Drugs Market
|
Report Coverage |
Details |
|
Market Size |
US$ 65.1 Billion by 2030 |
|
Growth Rate |
CAGR of 4.1% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Drug class, type, application and Region, |
|
Companies Mentioned |
Gilead Sciences, Inc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Cipla Inc.; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd. |
Antiviral Drugs Market Trends
The COVID-19 pandemic has boosted antiviral medicine sales. The market is growing due to a sudden rise in the number of COVID-19 cases and the primary focus of medical facilities on the treatment of COVID-19 patients. Furthermore, several pharmaceutical companies are focusing on new drug development in order to provide more effective treatment and better patient results. For instance, Cipla Inc. teamed with Gilead Sciences in May 2020 to manufacture and distribute remdesivir to treat COVID-19 patients in over 127 countries. As a result, aggressive collaborations and strategic efforts by market competitors to widen their antiviral medication manufacturing capacities in order to serve a large patient base have fueled the global market share.
The global anti-viral medications market share is being pushed by an increase in the reported rate of viral disorders. Furthermore, an increase in R&D activities and the expansion of more recent and updated details, like vaccinations and combined therapy, are expected to drive the antiviral drug market.
The production of a safe, efficient, and targeted antiviral from the structure to the ground requires time and limits the market revenue and profit. Potential viral pandemics emphasize the need for broad-spectrum antiviral medications, such as direct-acting antivirals, that can be rapidly deployed on a large scale to prevent viral spread until adequate vaccines are developed. Increasing infection prevention methods and vaccination accessibility knowledge is also expected to restrict the market of antiviral drugs.
Increased partnerships for antiviral drug development and manufacturing are expected to result in the development of several innovative drugs in the forecast period. The leading competitors in the market are collaborating on the research and development of innovative treatments to reduce the strain of virus antiviral drugs. For instance, In December 2021, Cipla Limited announced the acquisition of approximately 33% of an equity stake in Clean Max Auriga Power Limited Liability Partnership. The agreement is aligned with the business' goal to grow the use of renewable resources in its activities and to achieve the legal standards for just being a captive user under power generation regulations.
Drug Class Insights
The reverse transcriptase inhibitors segment dominated the market for antiviral drugs and accounted for the largest revenue share of 50.0% in 2021. The segment is anticipated to maintain its dominance over the forecast period. The high share of reverse transcriptase inhibitors can be attributed to the increasing diagnosis and treatment rate of HIV, as these medicines are mainly used to treat HIV infection and the high effectiveness of these drugs against viral infections. Moreover, the presence of reverse transcriptase inhibitors in the pipeline will fuel the demand for these drugs in the coming years. The drug class includes Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
The protease inhibitors segment held the second-largest revenue share in 2021 and is anticipated to witness a CAGR of -1.9% over the forecast period. The decline in the segment growth can be attributed to increasing vaccination against viral infections and reduced R&D activities in the development of protease inhibitors.
Type Insights
The branded segment dominated the market and accounted for the largest revenue share of 57.9% in 2021. The segment is expected to maintain its dominance over the forecast period. Branded antiviral medicines such as Biktarvy, Genvoya, Triumeq, Mavyret, and Prezista hold a significant share of the market. The high adoption rate of branded drugs in the North American and European markets and the high cost of drugs are expected to drive the segment.
Increasing demand for the generic version of antiviral drugs in developing countries due to its cost-effectiveness is driving the generics segment. The generic antiviral drugs segment is highly competitive and price-sensitive. The presence of a large number of generic pharmaceutical manufacturers such as Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Mylan, and others make the market highly competitive for generic antiviral drugs.
Application Insights
The HIV segment dominated the market and held the largest revenue share of 45.8% in 2021. The segment is expected to witness the fastest growth rate over the forecast period. The high prevalence of HIV infection coupled with a high treatment rate, presence of branded drugs, and government initiatives to increase the treatment rate is estimated to drive the market at a higher growth rate. For instance, in 2019, the U.S. government announced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2030. The initiative seeks to reduce HIV infections and improve the diagnosis and treatment rate in the U.S. Moreover, the presence of strong pipeline drugs for HIV infection will also fuel market growth over the forecast period.
The hepatitis segment held the second-largest revenue share in 2021. Increasing vaccination against hepatitis A and B is affecting the growth adversely. Moreover, the outbreak of the COVID-19 pandemic has significantly increased the growth of the others segment in 2020. Due to COVID-19, the others segment share increased from 6.9% to 23.8% from 2019 to 2020.
Regional Insights
North America dominated the market and accounted for the largest revenue share in 2021. The region is expected to witness a CAGR of -2.0% over the forecast period. The market decline can be attributed to the loss of market exclusivity of branded drugs, increasing vaccination rate against viral infections, and government initiatives to reduce the incidence of viral infections. For instance, the U.S. government is undertaking various measures including investment in infectious diseases programs and promoting the R&D activities of innovative therapies to manage viral infections.
In Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate during the forecast period. The high growth of the market can be attributed to the increasing prevalence and treatment rate of viral infections, developing healthcare infrastructure in the region, and increasing awareness among people regarding infectious diseases. Moreover, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the increasing geriatric population in the region are some of the key factors driving the segment growth.
Recent Developments
Some of the prominent players in the Antiviral Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antiviral Drugs market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Antiviral Drugs Market Study:
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers